Clearside Biomedical, Inc., a biopharmaceutical company, engages in the developing and delivering treatments that restore and preserve vision for people with serious eye diseases. Its product includes CLS-AX, an axitinib for suprachoroidal injection which is in Phase 1/2a clinical trial. It also develops XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of macular edema associated with uveitis, diabetic macular edema, and macular edema associated with retinal vein occlusion. The company was incorporated in 2011 and is headquartered in Alpharetta, Georgia.
IPO Year: 2016
Exchange: NASDAQ
Website: clearsidebio.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
8/21/2024 | $6.00 | Buy | Chardan Capital Markets |
6/25/2024 | $5.00 | Outperform | Oppenheimer |
3/11/2022 | $11.00 → $10.00 | Market Outperform | JMP Securities |
12/15/2021 | $19.00 → $9.00 | Outperform | Wedbush |
7/29/2021 | $10.00 | Buy | HC Wainwright & Co. |
Submission status for CLEARSIDE BIOMEDICAL, INC's drug XIPERE (ORIG-1) with active ingredient TRIAMCINOLONE ACETONIDE has changed to 'Approval' on 10/22/2021. Application Category: NDA, Application Number: 211950, Application Classification: Type 3 - New Dosage Form
Submission status for CLEARSIDE BIOMEDICAL, INC's drug SUSVIMO (ORIG-1) with active ingredient RANIBIZUMAB has changed to 'Approval' on 10/22/2021. Application Category: NDA, Application Number: 211950, Application Classification: Type 3 - New Dosage Form
- CLS-AX is a Highly Potent Tyrosine Kinase Inhibitor Delivered Suprachoroidally Using Clearside's Proprietary SCS Microinjector® - - Topline Data Expected to be Reported During the Week of October 7, 2024 - ALPHARETTA, Ga., Aug. 27, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced the completion of the final participant visit in the Company's ODYSSEY Phase 2b clinical trial of CLS-AX (axitinib injectable suspension) in neovascular age-related macular degeneration (wet AMD). With this milestone complete, the study database
- Phase 2b ODYSSEY Trial in Wet AMD Remains on Track with Topline Data Expected in Late Q3 2024 - - ODYSSEY Safety Review Committee Recommends Trial Continue as Planned with no Serious Adverse Events Observed - - Recent Key Opinion Leader Webinar Highlighted the Broad Applicability and Real-World Experience of Suprachoroidal Drug Delivery - ALPHARETTA, Ga., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), today reported financial results for the second quarter ended June 30, 2024, and provided a corporate update. "Our P
ALPHARETTA, Ga., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced that management will present a corporate update at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference which will be available on demand on Thursday, August 15, 2024, at 7:00 a.m. ET. Victor Chong, MD, MBA, Chief Medical Officer, will also participate in a panel discussion on the Evolving Therapeutic Landscape of AMD. A link to the live and archived webcast presentation may be accessed on the Clearside website under the Investors section: Event
ALPHARETTA, Ga., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its second quarter 2024 financial results will be reported on Monday, August 12, 2024, after the close of the financial markets. In lieu of a second quarter 2024 conference call, the Company hosted a Suprachoroidal Delivery Key Opinion Leader Webinar on Wednesday, July 24, 2024. The replay of this event is available on the Clearside website under the Investors section: Events and Presentations. Quarterly earnings conference calls are expected to
ALPHARETTA, Ga., July 29, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced that its partner, Arctic Vision, reported positive topline results from its Phase 3 clinical trial of ARCATUS® (ARVN001) for the treatment of Uveitic Macular Edema (UME) in China. In addition, Arctic Vision announced that new drug applications (NDAs) for ARCATUS have been officially accepted in Australia and Singapore. ARCATUS is Arctic Vision's name for XIPERE® (triamcinolone acetonide injectable suspension) for suprachoroidal use which was originally dev
ALPHARETTA, Ga., July 22, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), has opened registration for its virtual key opinion leader (KOL) event on Wednesday, July 24, 2024 from 8:00 - 9:15 am ET. To register for the event, click here. The event will highlight the broad applicability and real-world experience with suprachoroidal drug delivery, the SCS as a differentiator in the retinal treatment landscape with a focus on neovascular age-related macular degeneration (wet AMD), and ongoing SCS clinical programs, including potential future d
ALPHARETTA, Ga., July 11, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today the appointment of Glenn C. Yiu, M.D., Ph.D., Professor of Ophthalmology at the University of California, Davis, to its Scientific Advisory Board (SAB), which is comprised of industry-leading retinal physicians who provide medical and scientific expertise and input on the Company's research and development programs. "We are privileged to welcome Dr. Yiu to our SAB, given his leadership in the research and adoption of new delivery approaches for t
- Webinar to be held on Wednesday, July 24, 2024 at 8:00 am ET - - Retina Specialists to Provide Insights and Real-World Experience with Suprachoroidal Drug Delivery - - Target Profile for CLS-AX in Wet AMD Landscape and Potential Opportunities for Clearside Pipeline Expansion - ALPHARETTA, Ga., June 27, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced plans to host a virtual key opinion leader (KOL) event on Wednesday, July 24, 2024 from 8:00 - 9:15 am ET. The event will highlight the broad applicability and real-world experi
- Phase 2b ODYSSEY Trial in Wet AMD Remains on Track with Topline Data Expected Q3 2024 - - Strengthened Management Team and Board of Directors with Two Key Additions -- Management to Host Webcast and Conference Call Today at 4:30 P.M. ET - ALPHARETTA, Ga., May 09, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), today reported financial results for the first quarter ended March 31, 2024, and provided a corporate update. "As we near the midpoint of 2024, I am excited to highlight key aspects of our program and the steps we have taken to
ALPHARETTA, Ga., May 08, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that George Lasezkay, Pharm.D., J.D., President and Chief Executive Officer, and Victor Chong, M.D., MBA, Chief Medical Officer, will participate in a Fireside Chat at the Citizens JMP Life Sciences Conference on Tuesday, May 14, 2024, at 9:30 a.m. ET in New York, NY. A link to the live and archived webcast may be accessed on the Clearside website under the Investors section: Events and Presentations. An archive of the webcast will be available for
Needham analyst Serge Belanger reiterates Clearside Biomedical (NASDAQ:CLSD) with a Buy and maintains $4 price target.
Oppenheimer initiated coverage on Clearside Biomedical Inc (NASDAQ:CLSD), a biopharmaceutical company focused on delivering therapies to the back of the eye through the suprachoroidal (SCS) space. Oppenheimer writes, “We consider Clearside a pioneer in suprachoroidal delivery via its suprachoroidal Microinjector that improves delivery of therapies for retinal diseases.” Suprachoroidal drug delivery is an ocular route of drug administration. The analyst writes that intravitreal injections have traditionally been the standard for delivering retinal treatments, but they can cause issues like uncontrolled dispersion. Meanwhile, SCS injections provide a more targeted and compartmental
Oppenheimer analyst Andreas Argyrides initiates coverage on Clearside Biomedical (NASDAQ:CLSD) with a Outperform rating and announces Price Target of $5.
Gainers Sharps Technology (NASDAQ:STSS) stock increased by 56.5% to $0.4 during Wednesday's after-market session. The market value of their outstanding shares is at $6.3 million. Geovax Labs (NASDAQ:GOVX) shares moved upwards by 21.71% to $2.27. The market value of their outstanding shares is at $5.2 million. NexImmune (NASDAQ:NEXI) stock increased by 9.52% to $3.45. The company's market cap stands at $4.7 million. As per the news, the Q1 earnings report came out 2 days ago. Cognition Therapeutics (NASDAQ:CGTX) stock rose 8.04% to $2.83. The market value of their outstanding shares is at $113.3 million. Clearside Biomedical (NASDAQ:CLSD) shares rose 7.39% to $1.45. The market value of t
Expert Panel of Ophthalmologists Developed Professional Guidelines in Using the Innovative Technique for Retinal Therapeutic Delivery. Current Clinical Evidence and Physician Experience Support SCS Injection as a Safe and Effective Method for Delivering Retinal and Choroidal Therapeutics
The Dow Jones index closed higher by around 350 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company’s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga’s insider transactions platform. Sabre The Trade: Sabre Corporation (NASDAQ:SABR) Executive Vice President Roshan Mendis bought a total of 31,067 shares at an average price of $3.15. To acquire these shares, it cost around $97,802. What's Happening: On May 2, Sabre reporte
HC Wainwright & Co. analyst Yi Chen maintains Clearside Biomedical (NASDAQ:CLSD) with a Buy and lowers the price target from $6 to $5.
Needham analyst Serge Belanger reiterates Clearside Biomedical (NASDAQ:CLSD) with a Buy and maintains $4 price target.
4 - Clearside Biomedical, Inc. (0001539029) (Issuer)
3/A - Clearside Biomedical, Inc. (0001539029) (Issuer)
4 - Clearside Biomedical, Inc. (0001539029) (Issuer)
4 - Clearside Biomedical, Inc. (0001539029) (Issuer)
4 - Clearside Biomedical, Inc. (0001539029) (Issuer)
4 - Clearside Biomedical, Inc. (0001539029) (Issuer)
4 - Clearside Biomedical, Inc. (0001539029) (Issuer)
4 - Clearside Biomedical, Inc. (0001539029) (Issuer)
4 - Clearside Biomedical, Inc. (0001539029) (Issuer)
4 - Clearside Biomedical, Inc. (0001539029) (Issuer)
10-Q - Clearside Biomedical, Inc. (0001539029) (Filer)
8-K - Clearside Biomedical, Inc. (0001539029) (Filer)
8-K - Clearside Biomedical, Inc. (0001539029) (Filer)
8-K - Clearside Biomedical, Inc. (0001539029) (Filer)
S-8 - Clearside Biomedical, Inc. (0001539029) (Filer)
10-Q - Clearside Biomedical, Inc. (0001539029) (Filer)
8-K - Clearside Biomedical, Inc. (0001539029) (Filer)
ARS - Clearside Biomedical, Inc. (0001539029) (Filer)
DEFA14A - Clearside Biomedical, Inc. (0001539029) (Filer)
DEF 14A - Clearside Biomedical, Inc. (0001539029) (Filer)
4 - Clearside Biomedical, Inc. (0001539029) (Issuer)
4 - Clearside Biomedical, Inc. (0001539029) (Issuer)
4 - Clearside Biomedical, Inc. (0001539029) (Issuer)
4 - Clearside Biomedical, Inc. (0001539029) (Issuer)
4 - Clearside Biomedical, Inc. (0001539029) (Issuer)
4 - Clearside Biomedical, Inc. (0001539029) (Issuer)
4 - Clearside Biomedical, Inc. (0001539029) (Issuer)
4 - Clearside Biomedical, Inc. (0001539029) (Issuer)
SC 13G/A - Clearside Biomedical, Inc. (0001539029) (Subject)
SC 13G/A - Clearside Biomedical, Inc. (0001539029) (Subject)
SC 13G/A - Clearside Biomedical, Inc. (0001539029) (Subject)
SC 13D/A - Clearside Biomedical, Inc. (0001539029) (Subject)
SC 13G/A - Clearside Biomedical, Inc. (0001539029) (Subject)
SC 13G/A - Clearside Biomedical, Inc. (0001539029) (Subject)
SC 13G/A - Clearside Biomedical, Inc. (0001539029) (Subject)
SC 13G/A - Clearside Biomedical, Inc. (0001539029) (Subject)
SC 13G - Clearside Biomedical, Inc. (0001539029) (Subject)
SC 13G/A - Clearside Biomedical, Inc. (0001539029) (Subject)
Chardan Capital Markets initiated coverage of Clearside Biomedical with a rating of Buy and set a new price target of $6.00
Oppenheimer initiated coverage of Clearside Biomedical with a rating of Outperform and set a new price target of $5.00
JMP Securities reiterated coverage of Clearside Biomedical with a rating of Market Outperform and set a new price target of $10.00 from $11.00 previously
Wedbush resumed coverage of Clearside Biomedical with a rating of Outperform and set a new price target of $9.00 from $19.00 previously
HC Wainwright & Co. initiated coverage of Clearside Biomedical with a rating of Buy and set a new price target of $10.00
Wedbush reiterated coverage of Clearside Biomedical with a rating of Outperform and set a new price target of $18.00 from $6.00 previously
JMP Securities reiterated coverage of Clearside Biomedical with a rating of Market Outperform and set a new price target of $9.00 from $8.00 previously
Wedbush resumed coverage of Clearside Biomedical with a rating of Buy and set a new price target of $6.00
Wedbush resumed coverage of Clearside Biomedical with a rating of Buy and set a new price target of $5.00
ALPHARETTA, Ga., July 11, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today the appointment of Glenn C. Yiu, M.D., Ph.D., Professor of Ophthalmology at the University of California, Davis, to its Scientific Advisory Board (SAB), which is comprised of industry-leading retinal physicians who provide medical and scientific expertise and input on the Company's research and development programs. "We are privileged to welcome Dr. Yiu to our SAB, given his leadership in the research and adoption of new delivery approaches for t
ALPHARETTA, Ga., April 16, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that Anthony S. Gibney has been appointed to the Company's Board of Directors, effective April 15, 2024. "We are delighted to welcome Tony to our Board of Directors as we build on our leadership in delivering therapeutics to the suprachoroidal space," said Clay Thorp, Chair of the Clearside Board of Directors. "We believe Tony's significant experience driving value for biotech companies through successful pipeline development, financing, partnerin
ALPHARETTA, Ga., March 18, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that Victor Chong, M.D., MBA was appointed Chief Medical Officer on March 14, 2024. Dr. Chong is a board-certified retinal specialist with more than 25 years of experience as a retinal physician and navigating all phases of ophthalmic drug development. George Lasezkay, Pharm.D., J.D., President and Chief Executive Officer of Clearside, commented, "Victor is a well-known and well-respected retinal clinician and scientist, who is a strategically foc
ALPHARETTA, Ga., April 05, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), today announced the appointment of Arshad M. Khanani, M.D., M.A, F.A.S.R.S and Lejla Vajzovic, M.D., F.A.S.R.S to its Scientific Advisory Board (SAB). Clearside's SAB is comprised of industry leading retinal physicians who provide medical and scientific expertise and input on the Company's research and development programs. The SAB members are: Thomas A. Ciulla, M.D., M.B.A., ChairDavid S. Boyer, M.D.David M. Brown, M.D.Arshad M. Khanani, M.D., M.A., F.A.S.R.S
ALPHARETTA, Ga., June 14, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), today announced the appointment of Susan L. Coultas, Ph.D., as Chief Clinical Officer. In this role, Dr. Coultas serves as a member of the executive team and has overall responsibility for planning the initiation and execution of Clearside's clinical trials, including oversight of all clinical development operations. "We are very excited to have Susan join our team," said George Lasezkay, Pharm.D., J.D., Clearside's President and Chief Executive Officer. "With her b
ALPHARETTA, Ga., March 03, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that Benjamin R. Yerxa, Ph.D., has been appointed to the Company's Board of Directors, effective March 2, 2022. Dr. Yerxa currently serves as Chief Executive Officer of the Foundation Fighting Blindness, the world's leading private funding source for retinal degenerative disease research. "As we continue to expand Clearside's pipeline based on our proprietary SCS injection platform, we are pleased to add Dr. Yerxa, who brings deep scientific, ophtha
- Phase 2b ODYSSEY Trial in Wet AMD Remains on Track with Topline Data Expected in Late Q3 2024 - - ODYSSEY Safety Review Committee Recommends Trial Continue as Planned with no Serious Adverse Events Observed - - Recent Key Opinion Leader Webinar Highlighted the Broad Applicability and Real-World Experience of Suprachoroidal Drug Delivery - ALPHARETTA, Ga., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), today reported financial results for the second quarter ended June 30, 2024, and provided a corporate update. "Our P
ALPHARETTA, Ga., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its second quarter 2024 financial results will be reported on Monday, August 12, 2024, after the close of the financial markets. In lieu of a second quarter 2024 conference call, the Company hosted a Suprachoroidal Delivery Key Opinion Leader Webinar on Wednesday, July 24, 2024. The replay of this event is available on the Clearside website under the Investors section: Events and Presentations. Quarterly earnings conference calls are expected to
ALPHARETTA, Ga., April 30, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its first quarter 2024 financial results will be reported on Thursday, May 9, 2024 after the close of the financial markets. Management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update. The live and archived webcast may be accessed on the Clearside website under the Investors section: Events and Presentations. The live call can be accessed by dialing 888-645-4404 (U.S.) or
ALPHARETTA, Ga., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its fourth quarter and full year 2023 financial results will be reported on Tuesday, March 12, 2024 after the close of the financial markets. Management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update. The live and archived webcast may be accessed on the Clearside website under the Investors section: Events and Presentations. The live call can be accessed by dialing 888-50
- New Licensing Partnership with BioCryst Pharmaceuticals Expands Clearside's Proprietary Suprachoroidal Injection Platform to Plasma Kallikrein Inhibitor - - BioCryst Collaboration Provides $5 Million Upfront, the Potential for Additional $77.5 Million in Clinical, Regulatory, and Sales Based Milestone Payments, Plus Royalties - - Recruitment Completed in CLS-AX Phase 2b ODYSSEY Wet AMD Trial with Topline Data Expected in Q3 2024 - - Management to Host Webcast and Conference Call Today at 4:30 P.M. ET - ALPHARETTA, Ga., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the e
ALPHARETTA, Ga., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its third quarter 2023 financial results will be reported on Monday, November 13, 2023, after the close of the financial markets. Management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update. The live and archived webcast may be accessed on the Clearside website under the Investors section: Events and Presentations. The live call can be accessed by dialing 888-506-0062 (U.
- Phase 2b ODYSSEY Trial of CLS-AX in Wet AMD Progressing as Planned with Nearly 30 Sites Now Open - - Proprietary Suprachoroidal Injection Platform Featured in Peer-Reviewed Publication and at ARVO, ASRS and OIS Scientific Meetings - - Management to Host Webcast and Conference Call Today at 4:30 P.M. ET - ALPHARETTA, Ga., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), today reported financial results for the second quarter ended June 30, 2023 and provided a corporate update. "The last several months have been very productive
ALPHARETTA, Ga., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its second quarter 2023 financial results will be reported on Monday, August 14, 2023 after the close of the financial markets. Management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update. The live and archived webcast may be accessed on the Clearside website under the Investors section: Events and Presentations. The live call can be accessed by dialing (877) 545-0320 (U.
- Phase 2b ODYSSEY Trial of CLS-AX in Wet AMD Expected to Open Enrollment in Q2 2023 - - Positive Safety Data, Duration and Biologic Effect of CLS-AX Over 6 Months in OASIS Phase 1/2a Extension Study Highlighted in Presentations at Recent Medical Meetings - - Management to Host Webcast and Conference Call Today at 8:30 A.M. ET - ALPHARETTA, Ga., May 11, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), today reported financial results for the first quarter ended March 31, 2023 and provided a corporate update. "We have delivered a
ALPHARETTA, Ga., May 02, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its first quarter 2023 financial results will be reported on Thursday, May 11, 2023 before the open of the financial markets. Management will host a webcast and conference call at 8:30 a.m. Eastern Time to discuss the results and provide a corporate update. Registration for the live and archived webcast may be accessed on the Clearside website under the Investors section: Events and Presentations. To participate via telephone, please register in